Summary
Investors are concerned about Novo Nordisk's long-term sales growth as the clock ticks down on patent protection.
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Source & full coverage: this summary is aggregated from Free Malaysia Today Business, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at Free Malaysia Today Business →
